H101 Plus TACE for r/m HNSCC
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorWest China Hospital
About this trial
This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
Eligibility criteria
Qualifiers
Age between 18 and under 80 years old.
Pathologically confirmed head and neck malignancies (including nasopharyngeal carcinoma, oral cavity cancer, oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, salivary gland cancer, nasal cavity and paranasal sinus cancer, etc.); patients who have failed at least two lines of standard treatment (including cetuximab and immuno check point inhibitors).
Expected survival ≥3 months.
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-2.
Disqualifiers
Expected survival less than 3 months.
Positive pregnancy test for women of childbearing age.
Concurrent diseases or conditions that affect the patient's ability to enroll normally or safety during the study period.
Active psychiatric disorders or other psychological conditions that affect the patient's ability to sign the informed consent or understand the study.
Trial design
Treatments tested in this trial
- H101
- TACE
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov